BPC-157 in Dubai — Research Data & UAE Supply

What Is BPC-157?

BPC-157, also known as Body Protection Compound-157, is a synthetic pentadecapeptide composed of 15 amino acids. Its sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is derived from a protective protein naturally present in human gastric juice. Unlike many synthetic peptides, BPC-157 is stable in gastric acid, which is unusual for a peptide of this size and has contributed to its extensive preclinical investigation.

The peptide was first characterised in the early 1990s by researchers at the University of Zagreb, led by Professor Predrag Sikiric. Since then, over 100 preclinical studies have examined BPC-157 across models of tendon injury, ligament damage, muscle tears, inflammatory bowel conditions, gastric ulceration, and nerve damage. It remains an investigational compound with no regulatory approvals for therapeutic use in any jurisdiction.

• Classification: Synthetic pentadecapeptide (15 amino acids)
• Origin: Derived from human gastric juice protein BPC
• Molecular weight: 1,419.53 Da
• CAS number: 137525-51-0
• Stability: Resistant to gastric acid degradation (unlike most peptides)
• Status: Research compound — not approved for human or veterinary use

Research Data — Healing Studies

The preclinical evidence base for BPC-157 spans multiple tissue types. The following summarises key findings from the most-cited studies in the BPC-157 literature. All data below comes from animal models and in-vitro experiments — no completed human clinical trials have been published as of March 2026.

Tendon & Ligament Repair

Chang et al. (2011) demonstrated that BPC-157 accelerated Achilles tendon healing in a rat transection model. Treated groups showed significantly increased tendon-to-bone healing strength and improved collagen fibre organisation compared to controls. The proposed mechanism involves upregulation of growth hormone receptor expression and activation of the FAK-paxillin pathway, which promotes tendon fibroblast migration and proliferation.

Subsequent studies confirmed these findings across medial collateral ligament (MCL) models, with BPC-157-treated animals demonstrating faster return to biomechanical baseline compared to untreated controls.

Gut & Mucosal Protection

The gastric origin of BPC-157 has made gut research a primary focus area. Sikiric et al. (2022) published a comprehensive review covering cytoprotective effects on gastric mucosa, acceleration of mucosal healing in NSAID-induced ulcer models, and protective activity in experimental inflammatory bowel disease (IBD) models. BPC-157 appears to modulate the NO system, counteracting both excessive NO (L-arginine pathway) and NO depletion (L-NAME pathway).

Muscle Injury

In models of crush injury and muscle transection, BPC-157 administration resulted in faster functional recovery and reduced fibrosis at the injury site. Seiwerth et al. (2018) reviewed the muscle repair data alongside broader tissue-healing evidence, noting consistent angiogenic effects mediated through VEGF upregulation.

Angiogenesis & Vascular Effects

Multiple studies have reported that BPC-157 promotes new blood vessel formation (angiogenesis) at injury sites. This effect appears to be mediated through the VEGF pathway, with treated animals showing increased capillary density in healing tissue compared to controls. The angiogenic mechanism may underlie the cross-tissue healing effects observed in tendon, muscle, and gut models.

BPC-157 Availability in Dubai & the UAE

BPC-157 is available in Dubai and the wider UAE as a research peptide for in-vitro laboratory use. It is not classified as a registered pharmaceutical by the UAE Ministry of Health and Prevention (MoHAP), and it is not approved for human administration in any country. All BPC-157 products in the UAE should be clearly labelled “For Research Use Only” in accordance with MoHAP Circular 17/2022.

The UAE research peptide market has expanded significantly since 2024, driven by growing academic interest in regenerative peptide biology and the broader GLP-1/metabolic peptide research wave. Dubai-based researchers can source BPC-157 from local and international suppliers, but quality varies dramatically. For a full overview of the regulatory landscape and sourcing best practices, see our research peptides in the UAE guide.

How to Source BPC-157 in the UAE

When evaluating BPC-157 suppliers in Dubai, researchers should verify the following before purchasing:

• Third-party HPLC analysis: The Certificate of Analysis should come from an independent laboratory (e.g., Janoshik Analytical, Chromak Research), not from the supplier’s own in-house testing. Demand specific purity percentages, not rounded “99%+” claims.
• Mass spectrometry confirmation: LC-MS or MALDI-TOF verification confirms that the peptide is the correct sequence and molecular weight, not just pure.
• Cold-chain delivery: BPC-157 degrades in heat. In the UAE, where summer temperatures regularly exceed 45°C, temperature-controlled shipping from dispatch to receipt is essential. For detailed stability data, see our peptide stability and storage guide.
• Compliance labelling: All products must carry “For Research Use Only” disclaimers. Suppliers marketing BPC-157 for direct human use are operating outside the regulatory framework.

Dosing Protocols in Research Settings

The following dosing information is derived from published preclinical research protocols and is provided for reference purposes only. These are not dosing recommendations for human use.

Standard Research Protocols

• Dose range: 250–500mcg per administration (most common in published literature)
• Frequency: Once daily (QD) or twice daily (BID) — BID protocols are more common in acute injury models
• Route: Subcutaneous injection near the site of interest (most studied route); intraperitoneal injection also used in animal models
• Duration: Typical research protocols run 2–4 weeks
• Animal dose conversion: Preclinical studies commonly use 10mcg/kg body weight in rat models

Reconstitution

BPC-157 is typically supplied as a lyophilised (freeze-dried) powder that requires reconstitution before use. The standard procedure:

1. Allow the vial to reach room temperature (do not heat)
2. Add bacteriostatic water (BAC water) slowly along the vial wall — do not inject directly onto the powder
3. Swirl gently; do not shake or vortex
4. Standard reconstitution volume: 1–2mL BAC water per 5mg vial
5. Once reconstituted, refrigerate at 2–8°C and use within 14–21 days

For precise concentration calculations after reconstitution, use our peptide reconstitution calculator.

Storage & Handling

Proper storage is critical for maintaining BPC-157 peptide integrity, particularly in the UAE climate. Degraded peptides produce unreliable research results regardless of initial purity.

Key handling rules: protect from direct light, avoid repeated freeze-thaw cycles, and never store reconstituted peptides at room temperature. In the UAE, transit from courier to laboratory is a critical vulnerability — insist on cold-chain delivery from any supplier. For comprehensive storage guidance across all peptide types, see our peptide stability and storage guide.

BPC-157 vs TB-500 — Comparison

BPC-157 and TB-500 (Thymosin Beta-4 fragment) are the two most widely studied regenerative peptides in preclinical research. While both are investigated for tissue repair, they operate through distinct mechanisms and have different pharmacological profiles.

Some preclinical protocols investigate BPC-157 and TB-500 in combination, hypothesising complementary mechanisms — BPC-157 driving local angiogenesis while TB-500 promotes systemic cell migration to injury sites. However, combination data remains limited and largely anecdotal. Neither peptide is approved for therapeutic use.